Short-Term Visual Acuity and Intraocular Pressure Changes and Their Correlation after Anti-Vascular Endothelial Growth Factor Injection

Ophthalmologica

Volumn 236, Issue 1, 2016, Pages 36-42

  Lim, Hyung Bin ^a   Kim, Min Su ^a   Jo, Young Joon ^a   Kim, Jung Yeul ^a  

^a Chungnam National University College of Medicine   (South Korea)

Author keywords

Complication of intravitreal injection; Intraocular pressure; Intravitreal anti vascular endothelial growth factor injection; Visual acuity

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; APPLANATION TONOMETER; ARTICLE; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DRUG MECHANISM; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RETINAL DISEASES; TIME FACTOR;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL DISEASES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84963556432     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000445038     Document Type: Article

References (31)

1. Ohm J: Über die Behandlung der Netzhautablösung durch operative Entleerung der subretinalen Flüssigkeit und Einspritzung von Luft in den Glaskörper. Graefes Arch Clin Exp Ophthalmol 1911; 79: 442-450.
2. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB: Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2014; 158: 319-327.e2.
3. Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349.
4. el Matri L, Chebil A, Kort F, Bouraoui R, Baklouti K, Mghaieth F: Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010; 248: 779-784.
5. Bakri SJ, Larson TA, Edwards AO: Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246: 779-781.
6. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr: Risks of intravitreous injection: a comprehensive review. Retina 2004; 24: 676-698.
7. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y: Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008; 86: 372-376.
8. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P: Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18: 658-661.
9. Benz MS, Albini TA, Holz ER, Lakhanpal RR, Westfall AC, Iyer MN, Carvounis PE: Shortterm course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006; 113: 1174-1178.
10. Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A: Course of intraocular pressure after intravitreal injection of 0.05 ml ranibizumab (Lucentis). Eur J Ophthalmol 2010; 20: 174-179.
11. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
12. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113: 633.e1-e4.
13. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N: Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 623.e1.
14. Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007; 29: 1850-1861.
15. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
16. Mojica G, Hariprasad SM, Jager RD, Mieler WF: Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 2008; 92: 584.
17. He Z, Bui BV, Vingrys AJ: The rate of functional recovery from acute IOP elevation. Invest Ophthalmol Vis Sci 2006; 47: 4872-4880.
18. Van Buskirk EM, Cioffi GA: Glaucomatous optic neuropathy. Am J Ophthalmol 1992; 113: 447-452.
19. Van Buskirk EM, Cioffi GA: Predicted outcome from hypotensive therapy for glaucomatous optic neuropathy. Am J Ophthalmol 1993; 116: 636-640.
20. Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT: The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res 2005; 24: 39-73.
21. Bellezza AJ, Hart RT, Burgoyne CF: The optic nerve head as a biomechanical structure: initial finite element modeling. Invest Ophthalmol Vis Sci 2000; 41: 2991-3000.
22. Falkenstein IA, Cheng L, Freeman WR: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007; 27: 1044-1047.
23. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J: Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-811.
24. Sehi M, Flanagan JG, Zeng L, Cook RJ, Trope GE: Relative change in diurnal mean ocular perfusion pressure: a risk factor for the diagnosis of primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2005; 46: 561-567.
25. Hayreh SS, Kolder HE, Weingeist TA: Central retinal artery occlusion and retinal tolerance time. Ophthalmology 1980; 87: 75-78.
26. Hayreh SS, Weingeist TA: Experimental occlusion of the central artery of the retina. I. Ophthalmoscopic and fluorescein fundus angiographic studies. Br J Ophthalmol 1980; 64: 896-912.
27. Hayreh SS, Weingeist TA: Experimental occlusion of the central artery of the retina. IV. Retinal tolerance time to acute ischaemia. Br J Ophthalmol 1980; 64: 818-825.
28. Hayreh SS, Jonas JB: Optic disk and retinal nerve fiber layer damage after transient central retinal artery occlusion: an experimental study in rhesus monkeys. Am J Ophthalmol 2000; 129: 786-795.
29. Pong JC: Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2008; 246: 463-464; author reply 465-466.
30. Arnavielle S, Creuzot-Garcher C, Bron AM: Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2007; 245: 345-350.
31. Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM: Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 2010; 227: 280-284.